Antibiotics have saved millions of lives since they were first discovered. But over the years, many bacteria have learned how to survive these medicines, leading to a growing problem called Antibiotic resistance. Today, infections that were once easy to treat are becoming harder to cure. This is why the search for new antibiotics is one of the biggest challenges in modern medicine.
Recently, Wockhardt developed Zaynich, a novel antibiotic that has now been approved by the U.S. Food and Drug Administration (FDA) and The Drugs Controller General of India (DCGI). It is the second drug discovered and developed in India to receive FDA approval, marking an important milestone for Indian pharmaceutical research.
In the Phase 3 clinical trial involving 530 patients across multiple countries, it achieved an 89% success rate, compared with 68.4% for meropenem, one of the most powerful antibiotics currently used as a last-resort treatment. These results suggest that Zaynich could become an important new option when existing antibiotics fail.
Zaynich combines two medicines – Cefepime, an antibiotic, and Zidebactam, a novel drug that boosts cefepime’s ability to attack bacteria. Think of a bacterium as a house protected by strong walls. Most antibiotics try to break down one part of that wall. Zaynich attacks multiple weak points at the same time, making it much harder for the bacteria to defend itself or develop resistance. This breakthrough is crucial globally, as antimicrobial resistance is one of the top global public health threats of our time, according to the World Health Organization (WHO). New antibiotics are essential for safe surgeries, cancer treatments, and treating infections. This discovery underscores the ongoing nature of scientific efforts, with each finding contributing to human health. Continued research and responsible antibiotic use enhance our chances against harmful bacteria.
